| | | | | S-1 | | | |
| | | | | S-3 | | | |
| | | | | S-5 | | | |
| | | | | S-7 | | | |
| | | | | S-9 | | | |
| | | | | S-74 | | | |
| | | | | S-75 | | | |
| | | | | S-77 | | | |
| | | | | S-79 | | | |
| | | | | S-84 | | | |
| | | | | S-91 | | | |
| | | | | S-91 | | | |
| | | | | S-91 | | | |
| | | | | S-91 | | |
| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 3 | | | |
| | | | | 5 | | | |
| | | | | 5 | | | |
| | | | | 6 | | | |
| | | | | 15 | | | |
| | | | | 22 | | | |
| | | | | 23 | | | |
| | | | | 24 | | | |
| | | | | 27 | | | |
| | | | | 28 | | | |
| | | | | 30 | | | |
| | | | | 32 | | | |
| | | | | 32 | | |
| | |
As of June 30, 2021
|
| |||||||||
| | |
Actual
|
| |
As
Adjusted |
| ||||||
| | |
(unaudited)
|
| |||||||||
| | |
(in thousands)
|
| |||||||||
Cash, cash equivalents and available for sale securities(1)
|
| | | $ | 159,882 | | | | | $ | | | |
Preferred stock, par value $0.001 per share; 5,000,000 shares authorized, no shares issued or outstanding, actual and as adjusted
|
| | | | — | | | | | | — | | |
Common stock, $0.001 par value: 200,000,000 shares authorized, actual and as adjusted; 90,386,770 shares issued and outstanding, actual; shares issued and outstanding, as adjusted
|
| | | | 90 | | | | | | | | |
Additional paid-in capital
|
| | | | 761,491 | | | | | | | | |
Accumulated deficit
|
| | | | (622,011) | | | | | | | | |
Accumulated other comprehensive income
|
| | | | 3 | | | | | | | | |
Total stockholders’ equity
|
| | | | 139,573 | | | | | | | | |
Total capitalization
|
| | | $ | 299,455 | | | | | $ | | | |
|
Public offering price per share
|
| | | | | | | | | $ | | | |
|
Net tangible book value per share as of June 30, 2021
|
| | | $ | 1.54 | | | | | | | | |
|
Increase in net tangible book value per share attributable to new investors in this offering
|
| | | $ | | | | | | | | | |
|
As adjusted net tangible book value per share after this offering
|
| | | | | | | | | $ | | | |
|
Dilution per share to new investors in this offering
|
| | | | | | | | | $ | | | |
Underwriter
|
| |
Number of
Shares |
| |||
Morgan Stanley & Co. LLC
|
| | | | | | |
Cowen and Company, LLC
|
| | | | | | |
Stifel, Nicolaus & Company, Incorporated
|
| | | | | | |
Credit Suisse Securities (USA) LLC
|
| | | | | | |
Total
|
| | | | | | |
| | | | | |
Total
|
| |||
| | |
Per Share
|
| |
Without
Exercise of Option to Purchase Additional Shares |
| |
With Full
Exercise of Option to Purchase Additional Shares |
|
Public offering price
|
| | | | | | | | | |
Underwriting discount
|
| | | | | | | | | |
Proceeds, before expenses, to IVERIC bio, Inc.
|
| | | | | | | | | |
| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 3 | | | |
| | | | | 5 | | | |
| | | | | 5 | | | |
| | | | | 6 | | | |
| | | | | 15 | | | |
| | | | | 22 | | | |
| | | | | 23 | | | |
| | | | | 24 | | | |
| | | | | 27 | | | |
| | | | | 28 | | | |
| | | | | 30 | | | |
| | | | | 32 | | | |
| | | | | 32 | | |
|
Morgan Stanley
|
| | Cowen | | | Stifel | | |
Credit Suisse
|
|